Actemra IV (tocilizumab) / Roche, JW Pharma, Cipla, Chugai Pharmaceutical - LARVOL DELTA

Isolated tracheobronchial relapsing polychondritis: A masquerader of chronic airway disease (ERS 2026) - "She had been diagnosed with RP and treated with corticosteroids (CS) and tocilizumab (TCZ) for several years leading to stabilization of obstructive ventilatory impairment on pulmonary function testing...Biologic drugs are frequently used as CS-sparing agents, mainly in airway involvement. However, the optimal choice and duration of biologic therapy remain unclear."

Pulmonary Disease • Respiratory Diseases

Epidemiology of respiratory viral infections among hematopoietic cellular therapy and chimeric antigen receptor T-cell therapy recipients in the post COVID-19 era. (PubMed, Haematologica) - "Among the194 episodes, 151 (78%) were upper respiratory tract infections, and 43 (22%) were lower respiratory tract infections (LRTIs); 49% (21/43) of LRTIs were severe. In multivariate analysis, severe RVI was associated with the use of tocilizumab within 30 days of RVI (OR 4.84 95% CI 1.12-20.96, p=0.035), low ALC (."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Transplantation

Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis (ASH 2023) - P1/2 | "BTK inhibitors, ibrutinib and acalabrutinib are immunomodulatory and may enhance CAR-T expansion, engraftment and tumor clearance while decreasing the frequency and severity of CRS in chronic lymphocytic leukemia (Qin, et al...Three (20%) patients had grade 3 ICANS which resolved with dexamethasone and anakinra or tocilizumab...Conclusions Acalabrutinib successfully bridged most patients in this trial when given concurrently with axi-cel and safely maintained high CR rates. CRP and ferritin levels were typically only modestly elevated after cell infusion. Severe CRS was not observed and high-grade ICANS was uncommon."

CAR T-Cell Therapy • Clinical • Combination therapy • IO biomarker • P1/2 data • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • IL6 • MYC

Predictive and pharmacodynamic biomarkers for combination therapy in stage III-IV melanoma: A Simon phase II trial (NCT03999749). (ASCOBT 2024) - P2 | "Our findings suggest that Th17 cells can serve as a toxicity biomarker for combination therapy with ipilimumab, nivolumab and tocilizumab. Circulating Treg cells and serum osteopontin have emerged as promising pharmacodynamic biomarkers."

Biomarker • Combination therapy • IO biomarker • P2 data • PK/PD data • Melanoma • Oncology • Solid Tumor • CD4 • DPP4 • IL23A • IL6 • SPP1

A Proof-of-Principle of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: A Phase 1a Pilot Cohort (ASH 2024) - P1 | "The feasibility outcome was achieved, as all pts successfully received SC-BRT and standard cyclophosphamide/fludarabine LD followed by commercial lisocabtagene maraleucel (n=4) or axicabtagene ciloleucel (n=2)...One patient was treated with steroids and tocilizumab for mild CRS and the patient with grade 5 CRS received steroids, tocilizumab and siltuximab but expired on day +6...This is the first reported delivery of any form of RT following administration of LD chemotherapy potentially opening the door for novel CART conditioning approaches. Given successful completion of Phase 1a, 14 additional patients are now being recruited to the Phase 1b expansion cohort (9 already accrued, data not presented) to confirm safety, assess preliminary outcomes and explore possible immune augmentation."

CAR T-Cell Therapy • P1 data • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • PTPRC

Navigating Bispecifics Outpatient Step-Up Dosing: A Roadmap to Help Improve Safety and Access in the Real-World (NORTHSTAR) (SOHO 2026) - "Context: BsAbs, including teclistamab and talquetamab, have significantly improved outcomes in RRMM. Teclistamab in combination with daratumumab has demonstrated unprecedented efficacy in patients with one or more prior line of treatment...Providers emphasized prophylactic tocilizumab to reduce CRS risk and severity, patient and caregiver education on AEs, and access to and instructions for at-home AE monitoring equipment (thermometers, pulse oximeters, etc) and management... Experts agreed that outpatient SUD is feasible for most patients and can be safely implemented with appropriate education, monitoring, and care coordination, including access to emergency care. These findings will provide actionable guidance to support the development of a practical toolkit for outpatient BsAb initiation across diverse practice settings, enabling broader patient access and improved long-term outcomes. AE: adverse event, BsAbs: bispecific antibodies, CRS: cytokine release syndrome,..."

Bispecific • Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Oncology

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Recruiting

Enrollment open • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Clinical and laboratory manifestations and treatment of children with TNFRSF1A gene variants. (PubMed, World J Clin Pediatr) - "Variants in the TNFRSF1A gene may cause a wide range of clinical symptoms, including eye and intestinal lesions that are not typical of sJIA. All patients with fever and unusual sJIA symptoms should have molecular genetic testing for TNFRSF1A variants to confirm or exclude AID early. Early diagnosis enables timely therapy and prevents complications. Tocilizumab (39.3%), canakinumab (33.3%), and TNF inhibitors (21.2%) achieved remission in children with TNFRSF1A variants. Some patients required multiple bDMARD switches to achieve remission, highlighting the complexity of treatment decisions in this group."

Journal • Amyloidosis • CNS Disorders • Gastrointestinal Disorder • Idiopathic Arthritis • Immunology • Infectious Disease • Inflammation • Oncology • Otorhinolaryngology • Pain • Pediatrics • Rheumatology • Ventriculomegaly • TNFRSF1A

Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004. (ASCO 2023) - P1/2 | "Background: In patients (pts) with R/R CLL/SLL that progressed on BTKi and failed venetoclax (ven)-based regimens, achieving CR with current treatment is uncommon...In the safety set, rate of any-grade CRS was 84.6% (gr 3, 8.5%; no gr 4/5) and neurological events (NE) was 45.3% (gr 3, 17.9%; gr 4, 0.9%; no gr 5); 69.2% received tocilizumab and/or corticosteroids for CRS/NEs... Liso-cel demonstrated durable CR/CRi, high uMRD rates, and a manageable safety profile in pts with heavily pretreated, high-risk R/R CLL/SLL and high unmet need. Clinical trial information: NCT03331198. >an (%) [95% CI]; bMedian (95% CI), mo."

Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Rare Diseases • Small Lymphocytic Lymphoma

Fixed-duration teclistamab and talquetamab for frail patients with newly diagnosed multiple myeloma: The EMN37 fitfix study (ASH 2025) - "The combination of daratumumab with bispecific antibodies may lead to deeper and moredurable responses that could enable a lenalidomide- and a dexamethasone-sparing regimen including atreatment-free interval (TFI) in the first-line therapy of frail NDMM patients...However, noformal comparison of efficacy or safety between Tec-Dara and Tal-Dara will be performed.To mitigate the risk of potential side effects, dose modifications and adequate supportive care areplanned, including prophylactic tocilizumab administration and prophylactic intravenousimmunoglobulin (IVIG) supplementation therapy.The study will be conducted in Italy (14 sites), the Netherlands (9), Spain (4), and Norway (2)...Theupdated status of the study will be presented at the meeting.The study is conducted by the European Myeloma Network (EMN), in collaboration with HOVON, NMSG,EMN Italy, and PETHEMA and in collaboration with and with the financial support of JanssenPharmaceutica NV, a member of the Johnson..."

Clinical • Hematological Malignancies • Multiple Myeloma

A phase 1 study of in situ Immunomodulation with CDX-301, radiotherapy, CDX-1140, and Poly-ICLC ± pembrolizumab and tocilizumab – Safety and preliminary antitumor activity in patients with unresectable and metastatic solid tumors (ESMO 2026) - No abstract available

Clinical • Immunomodulating • Metastases • P1 data • Oncology • Solid Tumor

Preliminary Safety and Tolerability of CD19x22 CAR-T Cell Therapy in Adolescent and Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (ASH 2024) - P1/2 | "Pts with R/R LBCL and mantle cell lymphoma (MCL) who had received at least two lines of prior therapy were eligible and received a single infusion after a 3-days of fludarabine and cyclophosphamide lymphodepleting chemotherapy...CRS was managed with Tocilizumab and steroids...IEC-HS was treated with steroids, anakinra, and ruxolitinib...The trial is currently ongoing, and updated data will be presented at the meeting. This CAR is also being tested in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies and is reported separately (NCT05442515)"

CAR T-Cell Therapy • Clinical • IO biomarker • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Large B Cell Lymphoma • Leukemia • Lung Cancer • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • Rare Diseases • Solid Tumor • Thrombocytopenia • CD22

Interleukin-6 in hemolytic anemias: from inflammatory pathways to therapeutic targeting. (PubMed, Front Immunol) - "Current clinical evidence remains limited, but IL-6-directed therapy may be rational in selected refractory immune-mediated or macrophage-activation-associated hemolytic disorders. Future studies should prioritize mechanism-based biomarkers and prospective, biomarker-stratified trials."

Journal • Review • Anemia • Autoimmune Hemolytic Anemia • Cardiovascular • Complement-mediated Rare Disorders • Genetic Disorders • Hematological Disorders • Immunology • Inflammation • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases • Sickle Cell Disease • Thrombosis • IL6

Bevacizumab and Tocilizumab for Recurrent Adamantinomatous Craniopharyngioma: A Case Series (SNO 2026) - No abstract available

Clinical • Brain Cancer • CNS Tumor

Establishing T Cell–Engaging Bispecific Antibody Therapy in Community Practice (SOHO 2026) - "Introduction: T cell–engaging bispecific antibodies (TCEs) are increasingly used for relapsed or refractory malignancies, but implementation outside academic centers remains challenging because of step-up dosing requirements, cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), supportive care needs, infections, and the requirement for immediate access to tocilizumab...Therapies included tarlatamab (n = 13), talquetamab (n = 6), teclistamab (n = 2), glofitamab (n = 3), and mosunetuzumab (n = 1)... A structured multidisciplinary care model (navigator, coordinator, infusion nurse, pharmacist, advanced nurse practitioner, hospitalist) incorporating standardized protocols, caregiver engagement, and rapid physician access enables safe, effective delivery and broader adoption of TCEs in the community."

Bispecific • Oncology

Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC). (ASCO 2025) - P1 | "Pre-medication with dexamethasone (16 mg) was required in SU and 1st TD...Pts had a median of 4 prior therapies (range 1-13; 99.4% ARPI, 78.2% taxane chemotherapy, 17.2% lutetium Lu 177 vipivotide tetraxetan)...In the RP2D safety population (n=45; 3.5 mg [Day 1], 18 mg [Day 8], 300 mg Q3W or Q6W IV), the most common TRAEs were infusion-related reactions (22.2%; Gr 1/2), fatigue (15.6%; Gr 1/2), and CRS (8.9%; all Gr 1, no tocilizumab was administered), no TRAEs led to treatment discontinuation, no ICANS was observed, and 2 serious TRAEs (Gr 1 CRS) were reported... Pasritamig was very well tolerated (<10% of pts experienced CRS [all Gr1] at the RP2D) with promising antitumor activity, demonstrating proof of concept for KLK2 as a target amenable to T-cell redirection. These results address an unmet need for a targeted T-cell based therapy that is safe to administer in an outpatient setting with clinically meaningful benefit in mCRPC. Phase 3 trials are planned."

Metastases • P1 data • Castration-Resistant Prostate Cancer • Fatigue • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • KLK2

B cell subtype is a predictive and pharmacodynamic biomarkers for combination therapy in stage III-IV melanoma: a simon phase II trial (AACR 2025) - "Our findings suggest that naive B cells could serve as a toxicity biomarker in combination therapy with ipilimumab, nivolumab, and tocilizumab. Late memory B cells emerged as a promising pharmacodynamic biomarker. Immunological monitoring may help elucidate the mechanisms of irAEs and predict irAE occurrence."

Biomarker • Combination therapy • IO biomarker • P2 data • PK/PD data • Melanoma • Oncology • Solid Tumor • IL6

Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial (ASH 2025) - P3 | "Background MagnetisMM-6 (NCT05623020) is an open-label, 2-arm, randomized, phase 3 study evaluating ELRA incombination with DARA and R (EDR) versus DARA, R, and dexamethasone in patients (pts) withtransplant-ineligible (TI) or -deferred (TD) newly diagnosed multiple myeloma (NDMM). These data demonstrate that debulking prior to ELRAadministration is not needed, which may be especially important in pts with NDMM. In the absence ofprophylactic tocilizumab, ELRA continues to demonstrate a predictable CRS profile with most eventsbeing low grade and occurring during step-up dosing."

Clinical • Combination therapy • Cytokine release syndrome • Hematological Malignancies • Multiple Myeloma • Oncology

A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma (ASH 2021) - P2 | "CD19 CAR products included axicabtagene (23 pts; 74%), tisagenlecleucel (4 pts; 13%) and brexucabtagene (4 pts; 13%). Early use of IL-1 receptor inhibitor anakinra appears to be safe and feasible, and reduces the rates of both severe CRS and ICANS with the comparable response rates in adult pts with R/R B-cell lymphoma receiving CD19 CAR T cells. The overall severe CRS and ICANS rates were 6% each with relatively low utilization of tocilizumab (29%) and corticosteroids (19%). In pts receiving axicabtagene, the rate of severe ICANS was 4%."

CAR T-Cell Therapy • Clinical • P2 data • Critical care • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Inflammation • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma With High Disease Burden: Experience From an LMIC Community-Based Non-ICU Setting (SOHO 2026) - "With appropriate IVIG, antimicrobial, and tocilizumab prophylaxis, teclistamab can be safely administered in non-ICU LMIC community settings for patients with high-burden RRMM lacking access to advanced cellular therapies, giving a new lease on life to those who cannot travel for such treatments. ASCT: autologous stem cell transplantation, CART: chimeric antigen receptor T-cell, CRS: cytokine release syndrome, Dara-VLd: daratumumab, bortezomib, lenalidomide, and dexamethasone, ICANS: immune effector cell–associated neurotoxicity syndrome, ICU: intensive care unit, IVIG: intravenous immunoglobulin, RRMM: relapsed/refractory multiple myeloma."

Hematological Malignancies • Multiple Myeloma • Oncology

Second-Week Onset and High Mortality of IEC-HS After CAR T-Cell Therapy in 1,931 Recipients (IMS 2026) - "Tocilizumab was used in 13 (65%), ruxolitinib in 4 (20%), plasma exchange in 15 (75%), and continuous renal replacement therapy or other blood purification in 9 (45%). IEC-HS was uncommon but carried a heavy treatment burden and poor survival. Onset clustered in the second postinfusion week, shortly after severe CRS, identifying a critical period for surveillance. Infection was the leading recorded cause of death, underscoring the need to evaluate and treat infection in parallel with control of hyperinflammation and timely transfusion and organ support."

CAR T-Cell Therapy • Late-breaking abstract • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Rare Diseases • IL10 • IL2 • IL6

Phase II trial of weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: Clinical outcomes and biomarker analysis. (ASCO 2024) - P2 | "To our knowledge, this is the first study to investigate toci in combination with high dose ipi3/nivo1. Although our cohort is small, preliminary data suggests IL-6R blockade using the DD regimen could decrease the rate of G 3/4 irAEs while maintaining antitumor responses of ipi3/nivo1. A randomized phase ll trial investigating this strategy is underway."

Biomarker • Clinical • Clinical data • IO biomarker • Metastases • P2 data • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Melanoma • Metabolic Disorders • Ocular Inflammation • Oncology • Ophthalmology • Pancreatitis • Solid Tumor • Type 1 Diabetes Mellitus • Uveitis • IL17A

Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update (ASH 2022) - P1b/2 | "All CRS events resolved (median time to resolution, 2 d; range, 1–4), no patients discontinued treatment due to CRS, and 5 patients received tocilizumab. In patients with R/R FL, subcutaneous epcoritamab + R2 demonstrated a manageable safety profile with only low-grade CRS events, mostly observed following the first full dose and all of which resolved. No new safety signals were detected. Data from this cohort are very encouraging with a high CMR rate observed in patients with R/R FL."

Clinical • P1/2 data • Fatigue • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Immune Modulation • Infectious Disease • Inflammation • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • CD20

A case report of ADMIO type 1 caused by a de novo STAT3 gain-of-function mutation. (PubMed, Front Immunol) - "Initial treatment with tocilizumab provided short-lived benefit. Following recurrent lymphadenitis and polyarthritis, adalimumab, tofacitinib, ruxolitinib emerged as a key anti-inflammatory intervention to treat the disease. This case enriches the rare disease database and helps raise clinicians' awareness of and attention to ADMIO type 1 disease."

Journal • Immunology • Rare Diseases • Rheumatology • Vasculitis • STAT3

Novel therapies for refractory idiopathic inflammatory myopathy-associated interstitial lung disease. (PubMed, Curr Opin Rheumatol) - "Across these agents, evidence is confined to case reports, small series, and observational cohorts, with few randomized trials reporting IIM-ILD-specific outcomes. Prospective studies are needed to define patient selection, treatment sequencing and combinations, durability, and safety of novel therapies in IIM-ILD."

Journal • Dermatomyositis • Immunology • Interstitial Lung Disease • Melanoma • Myositis • Oncology • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Rheumatology • Solid Tumor • IFIH1